Capiton buys Euro Vital Pharma from BC-backed Aenova

Capiton drew equity for the transaction from its €440m fifth buyout fund, which held a final close in January 2015.

The GP said it will finance bolt-on acquisitions to support Euro Vital's domestic and international growth.

Aenova employs a total of 4,300 people at 22 sites in eight European countries.

Previous funding
Euro Vital's parent, Aenova, is majority-owned by BC Partners, which acquired the business from Bridgepoint for €480m in 2012. It supported the acquisition of Euro Vital in December of the same year.

Company
Euro Vital was founded in 1992 and is headquartered in Hamburg. It develops, manufactures and sells medicine, health products and cosmetics in Germany.

People
Capiton – Manuel Hertweck (managing partner).
BC Partners – Stefan Zuschke (partner).

Advisers
Equity – Roland Berger (commercial due diligence); Deloitte (financial due diligence); EY (tax); Intargia (IT due diligence); AvS (management due diligence); Willis (insurance due diligence); Tauw (ESG due diligence); Fidelio Healthcare Partners (commercial due diligence).
Vendor – Ferber (corporate finance).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• Exits
• DACH
• Healthcare
• Germany
• capiton AG
• BC Partners
• Partial sale